Weaker prospects for pharmaceutical large Novo Nordisk A/S NVS have prompted Denmark’s financial ministry to chop its 2025 GDP forecast, now anticipating simply 1.4% progress, down 1.5 share factors from Might’s projection.
Progress is seen rebounding to 2.1% in 2026, up 0.7 factors. Employment continues to be rising and inflation is projected to remain under 2%. The ministry stated U.S. tariff hikes will additional weigh on exports and world exercise, whereas an EU-U.S. commerce framework reduces uncertainty round gross sales phrases.
Additionally Learn: New Weight problems Medicine Might See Premium Pricing Undermined By Underwhelming Information
Denmark’s progress outlook is being formed by shopper power, exports, and Novo Nordisk’s trajectory. Rising family demand, boosted by wage positive aspects, tax cuts, and excessive employment, is supporting non-public consumption.
Reuters famous Denmark’s sturdy 2024 progress was amongst Europe’s highest, with Novo Nordisk alone contributing one-fifth of employment positive aspects. However headwinds are mounting.
U.S. tariffs, for instance, dragged exports sharply decrease in early 2025, reducing forecast progress to 0.9% from 4.3% in Might.
In the meantime, Novo Nordisk—maker of Wegovy and Ozempic—introduced a worldwide hiring freeze and lowered its 2025 gross sales forecast to eight–14% progress, down from 13–21%, citing slower uptake of branded GLP-1 medication and rising competitors from Eli Lilly and compounded alternate options.
Nonetheless, Denmark’s financial system ministry raised its 2026 GDP outlook to 2.1%, pointing to stronger non-public and public spending.
Value Motion: NVO inventory is up 0.04% at $56.14 on the final verify on Friday.
Learn Subsequent:
Picture: Shutterstock
Market Information and Information dropped at you by Benzinga APIs
© 2025 Benzinga.com. Benzinga doesn’t present funding recommendation. All rights reserved.
